A Randomized, Double-Blind, Placebo-Controlled Trial Protocol Using the Fuzhengxiaoliu Patch for the Management of Primary Liver Cancer Pain

被引:0
|
作者
Li, Siman [1 ]
Wang, Binding [1 ]
Deng, Jiayao [2 ]
Li, Haiyan [2 ]
Wu, Yong [3 ]
Fang, Yu [2 ]
Yan, Bohua [2 ]
Chen, Yu [2 ]
机构
[1] Chengdu Univ TCM, Sch Clin Med, Chengdu, Sichuan, Peoples R China
[2] Hosp Chengdu Univ Tradit Chinese Med, Chengdu, Sichuan, Peoples R China
[3] Chengdu Zhongxiang Pharmaceut Technol Co Ltd, Chengdu, Sichuan, Peoples R China
来源
JOURNAL OF PAIN RESEARCH | 2025年 / 18卷
关键词
primary liver cancer; traditional Chinese medicine; Chinese herb; cancer pain management; randomized controlled trial; MECHANISMS;
D O I
10.2147/JPR.S500305
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: Chronic pain strongly affects the quality of life of patients with liver cancer pain. Safe and effective management of cancer- related pain is a worldwide challenge. Traditional Chinese medicine (TCM) has rich clinical experience in the treatment of cancer pain. The Fuzhengxiaoliu patch (FZXLP) is a compound TCM with the effects of detoxification and pain relief and has shown great efficacy in the treatment of patients with liver cancer, but high-quality clinical research that provides research-based evidence is lacking. We designed a randomized, double-blind, placebo-controlled trial to explore and evaluate the efficacy of FZXLP for the treatment of liver cancer pain. Methods: This is a prospective, randomized, double-blind, placebo-controlled trial. The trial will enrol 72 participants with primary liver cancer with cancer pain (damp-heat stagnation and toxin and blood stasis syndrome). The primary objective is to measure the reduction in pain using FZXLP in combination with tegafur, gimeracil and oteracil potassium capsule (S-1) compared to the placebo group with S-1. Pain will be measured by the number of opioids used, Chinese versions of the numerical rating scale (NRS), pain relief rate and number of breakthrough cases of cancer pain (BTcP). The secondary objectives include response evaluation criteria in solid tumors (RECIST), tumor markers, TCM syndrome scores, weight, functional assessment of cancer therapy-hepatobiliary (FACT-Hep) questionnaire scores, and self-rating anxiety scale scores. Adverse events (AEs) will be recorded throughout the study. Discussion: This study integrated TCM with clinical research to assess the efficacy and safety of the addition of FZXLP in the treatment of primary liver cancer pain. Trial registration: Chinese clinical trial registry, ChiCTR2300076951, Registered on October 25, 2023. https://www.chictr.org.cn/ showproj.html?proj=209608.
引用
收藏
页码:33 / 42
页数:10
相关论文
共 50 条
  • [41] Trimethoprim as Adjuvant Treatment in Schizophrenia: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial
    Shibre, Teshome
    Alem, Atalay
    Abdulahi, Abdulreshid
    Araya, Mesfin
    Beyero, Teferra
    Medhin, Girmay
    Deyassa, Negusse
    Negash, Alemayehu
    Nigatu, Alemayehu
    Kebede, Derege
    Fekadu, Abebaw
    SCHIZOPHRENIA BULLETIN, 2010, 36 (04) : 846 - 851
  • [42] A double-blind, placebo-controlled trial of topiramate for pathological gambling
    Berlin, Heather A.
    Braun, Ashley
    Simeon, Daphne
    Koran, Lorrin M.
    Potenza, Marc N.
    McElroy, Susan L.
    Fong, Timothy
    Pallanti, Stefano
    Hollander, Eric
    WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, 2013, 14 (02) : 121 - 128
  • [43] Psychological Treatment of Comorbid Insomnia and Depression: A Double-Blind Randomized Placebo-Controlled Trial
    Blom, Kerstin
    Forsell, Erik
    Hellberg, Monica
    Svanborg, Cecilia
    Jernelov, Susanna
    Kaldo, Viktor
    PSYCHOTHERAPY AND PSYCHOSOMATICS, 2024, 93 (02) : 100 - 113
  • [44] Sijunzi decoction granules in the prevention and treatment of recurrence of colorectal adenoma: Study protocol for a multicenter, randomized, double-blind, placebo-controlled trial
    Ni, Wenjing
    Liu, Tao
    Liu, Yujing
    Lu, Lu
    Zhou, Bingduo
    Dai, Yancheng
    Zhao, Hang
    Xu, Hanchen
    Ji, Guang
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [45] Efficacy and safety of Yirui capsule in patients with hyperlipidemia: study protocol for a multicenter, randomized, double-blind, placebo-controlled trial
    Dai, Liang
    Zhong, Linda L. D.
    Cao, Yan
    Chen, Wei
    Cheng, Ying
    Lin, Xiu-Fang
    Bian, Zhao-Xiang
    Lu, Ai-Ping
    TRIALS, 2016, 17
  • [46] Efficacy and safety of Yirui capsule in patients with hyperlipidemia: study protocol for a multicenter, randomized, double-blind, placebo-controlled trial
    Liang Dai
    Linda L. D. Zhong
    Yan Cao
    Wei Chen
    Ying Cheng
    Xiu-Fang Lin
    Zhao-Xiang Bian
    Ai-Ping Lu
    Trials, 17
  • [47] Systemically Acting Diclofenac Sodium Patch for Control of Low Back Pain: A Randomized, Double-Blind, Placebo-Controlled Study in Japan
    Taguchi, Toshihiko
    Yamaguchi, Shigeki
    Terahara, Takaaki
    Okawa, Koji
    Inakura, Hiroshi
    PAIN AND THERAPY, 2023, 12 (02) : 529 - 542
  • [48] Minocycline for sporadic and hereditary cerebral amyloid angiopathy (BATMAN): study protocol for a placebo-controlled randomized double-blind trial
    S. Voigt
    E. A. Koemans
    I. Rasing
    E. S. van Etten
    G. M. Terwindt
    F. Baas
    K. Kaushik
    A. C. G. M. van Es
    M. A. van Buchem
    M. J. P. van Osch
    M. A. A. van Walderveen
    C. J. M. Klijn
    M. M. Verbeek
    L. van der Weerd
    M. J. H. Wermer
    Trials, 24
  • [49] Systemically Acting Diclofenac Sodium Patch for Control of Low Back Pain: A Randomized, Double-Blind, Placebo-Controlled Study in Japan
    Toshihiko Taguchi
    Shigeki Yamaguchi
    Takaaki Terahara
    Koji Okawa
    Hiroshi Inakura
    Pain and Therapy, 2023, 12 : 529 - 542
  • [50] Efficacy of Xinbao pill on chronic heart failure: Study protocol of a multicenter, randomized, double-blind, placebo-controlled trial
    Wang, Yuanping
    Li, Jiahua
    Yan, Jiaqi
    Wang, Yulin
    Cheng, Yuanyuan
    Liu, Zhongqiu
    Wang, Dawei
    FRONTIERS IN PHARMACOLOGY, 2022, 13